FootPCCT: Detecting and Assessing Leg and Foot Stress Fractures Using Photon Counting CT

Sponsor
Balgrist University Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06024798
Collaborator
(none)
50
1
8
6.3

Study Details

Study Description

Brief Summary

Stress fractures (fatigue or insufficiency fracture) are caused by the mismatch between bone strength and chronic stress applied to the bone. The vast majority of these fractures occur in the lower extremity. Early-stage diagnosis is crucial to optimize patient care. Appropriate imaging is relevant in confirming diagnosis after clinical suspicion of stress fractures. Radiographs have low sensitivity, so a relevant number of fractures go undetected. MRI has a high sensitivity, but its availability is limited, and its respective examination time is prolonged. This study investigates the diagnostic accuracy of PCCT in lower extremity stress fractures as a dose-saving technology, guaranteeing an examination according to the ALARA-principle (as low as reasonably achievable).

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Photon-Counting-Computed-Tomography

Detailed Description

Stress fracture is caused by the mismatch between bone strength and chronical stress applied to the bone, which is insufficient to cause an acute fracture, but a stress fracture does not heal itself. One can subclassify it into fatigue fracture (overuse of a healthy bone) and insufficiency fracture (normal use of a weakened bone). Fatigue fractures usually happen in healthy athletes or military recruits, whereas insufficiency fracture appear in patients with underlying metabolic or nutritional disorder (e.g. osteoporosis). On radiographs and Computed Tomography (CT), stress fractures are defined as round or linear intracortical lucency or an intertrabecular sclerotic line, which rarely intersects the cortex. Radiograph is a cost-effective and highly available modality in detecting fractures, showing however a moderate sensitivity in detecting stress fractures: 15-35% on the initial and 30-70% on the follow-up imaging. CT, another modality highly available in most hospital settings, shows a similar moderate sensitivity of 32-38% with however a corresponding high specificity of 88-98% on initial imaging. Similar specificity values can be observed for magnetic resonance imaging (MRI) and nuclear scintigraphy. Although their availability is limited and their respective examination time is prolonged, they outperform the x-ray based technologies in term of sensitivity (68-98% MRI and 50-97% nuclear scintigraphy, respectively).

The introduction of dual-energy technology advanced CT from a pure anatomical evaluation tool to a combined anatomical and functional modality. Every material has a specific absorption number, which can be assessed by applying two different energies (high and low x-ray tube voltages). This method of multispectral imaging has been established and clinically implemented in detecting gout and characterizing renal stones. Further studies have shown that DECT can depict bone marrow edema, a marker of early stress fracture and a common finding in MRI. However, this has yet not been implemented in clinical practice.

The photon-counting-computed-tomography (PCCT) has been introduced recently, enabling an energy dependent separation of photons over the whole x-ray energy spectrum. This results in reduced background noise, improved image resolution and multispectral imaging without the necessity of an additional acquisition at a different energy level. An initial study has shown already shown the superiority of PCCT by better detecting and characterizing small renal stones, when compared to conventional dual-energy computed tomography (DECT).

In this project the investigators aim to include clinically referred patients with suspected stress fracture of the lower extremity who will have an MRI to confirm the diagnosis of a suspected stress fracture. The subjects will be scanned on the new PCCT system with dose saving technology, guaranteeing an examination according to the ALARA-principle (as low as reasonably achievable). The investigators will not inject iodine contrast media and they will expect a median dose of 2-4 mSv (millisieverts). Since this will not exceed the threshold of 5 mSv, this project will be classified as category A.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
50 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Assessing Patients With Suspected Stress or Insufficiency Fracture of the Lower Extremity With Photon-Counting-Computed-Tomography
Anticipated Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Feb 1, 2024
Anticipated Study Completion Date :
May 1, 2024

Outcome Measures

Primary Outcome Measures

  1. Presence of a fracture [Day 1, 4weeks follow up assessment]

    Presence/absence of a fracture

Secondary Outcome Measures

  1. Presence of bone edema [Day 1, 4weeks follow up assessment]

    Presence/absence of bone edema

  2. Presence of soft tissue edema [Day1, 4weeks follow up assessment]

    Presence/absence of soft tissue edema

Other Outcome Measures

  1. Pain localization [Day 1, 4 weeks follow up assessment, 12 weeks follow up assessment]

    Pain localization will be done through a clear statement of anatomical location

  2. Pain character [Day 1, 4 weeks follow up assessment, 12 weeks follow up assessment]

    Pain will be characterized using the following terms: sharp, dull, aching, burning, radiating, numbing, and pulsating.

  3. Pain intensity [Day 1, 4 weeks follow up assessment, 12 weeks follow up assessment]

    Pain intensity will be described using the Number Rating Scale (NRS): a score of 0 corresponds to the absence of pain, while a score of 10 indicates the most intense pain ever experienced.

  4. Pain duration [Day 1, 4 weeks follow up assessment, 12 weeks follow up assessment]

    Pain duration is described in days (d).

  5. Karlsson Scoring Scale: Patient reported outcome regarding the stress fracture [Day 1, 4 weeks follow up assessment, 12 weeks follow up assessment]

    The Karlsson scoring scale is utilized to evaluate and quantify both the functional status and the extent to which the stress fracture affects an individual's quality of life. The scoring system comprises a total of 90 points, where 0 points represent the most severe condition and 90 points indicate an absence of any issues.

  6. Foot Function Index: Patient reported outcome regarding the stress fracture [Day 1, 4 weeks follow up assessment, 12 weeks follow up assessment]

    The Foot Function Index is utilized to evaluate and quantify both the functional status and the extent to which the stress fracture affects an individual's quality of life. The minimum score is 0% (no pain or difficulty), and maximum score is 100%

Eligibility Criteria

Criteria

Ages Eligible for Study:
16 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • ≥ 16 years of age. Minor study subjects can have an additional signature by the parent or legal guardian

  • Clinically suspected stress or insufficiency fracture of the lower extremity

  • Written consent of study participation

  • Patients who will have an MRI to confirm the diagnosis of a suspected stress fracture

Exclusion Criteria:
  • < 16 years of age

  • Pregnancy

  • Metal implants

  • Postoperative situation

  • Infection or tumorous disease affecting the lower extremity

Contacts and Locations

Locations

Site City State Country Postal Code
1 Balgrist University Hospital Zürich Zurich Switzerland 8008

Sponsors and Collaborators

  • Balgrist University Hospital

Investigators

  • Principal Investigator: Stephan Wirth, PD Dr.med., Balgrist University Hospital

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Balgrist University Hospital
ClinicalTrials.gov Identifier:
NCT06024798
Other Study ID Numbers:
  • W1024
First Posted:
Sep 6, 2023
Last Update Posted:
Sep 6, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 6, 2023